Market Snapshot
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 7.20 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Market Overview
The African contraceptive drugs and devices market is expected to register a CAGR of 7.2% during the forecast period.
The outbreak of the COVID-19 pandemic has pushed the healthcare industry into action, with a race to develop both therapeutic and preventive drugs. Exponentially increasing cases of the coronavirus worldwide are leading to the need for the development of novel treatments, with several clinical trials underway. Initially, the global COVID-19 outbreak and the lockdown scenario in various countries have imposed some challenges on the market, as hospitals and clinics were forced to suspend services to prevent the spread of the SARS-CoV-2 virus. The restrictions imposed by the government have significantly impacted the growth of the studied market during the initial period of the pandemic. As per the study published in August 2022 by the African Journal of Primary Health Care & Family Medicine, the COVID-19 pandemic aggravated the risk of sub-Saharan African women to HIV infection because of a multitude of factors, including child marriages, teenage pregnancies, dropping out of school, increase in the incidence of sexual and gender-based violence and reduced access to preventive and treatment services for HIV and sexually transmitted infections. In addition, the market growth is stabilizing in the current scenario after COVID-19 as the worldwide restrictions have eased down and various services have been resumed.
Certain factors propelling the market growth are increasing incidences of sexually transmitted diseases, an increasing rate of unintended pregnancies, and rising government initiatives.
An unintended pregnancy occurs from not using contraception or inconsistent and incorrect use of contraceptive methods. The growth of contraceptive markets is necessary to avoid unwanted pregnancies and their complications, especially in teenagers. Teenage pregnancy is a big problem in Africa. For instance, as per the data published by the UNFPA in June 2022, in Southern Africa, 65% of pregnancies were unintended, and 36% ended in abortion. The predominant cause of unintended pregnancy is sexual activity without effective contraception through choice or coercion. In many cases, unintended pregnancy is linked to gender-based violence, including early sexual debut that is non-consensual and child marriage. An increase in unplanned pregnancies has helped in the growth of the market.
In addition, the rising prevalence of sexually transmitted diseases among the population is expected to increase the market growth. For instance, the WHO estimates, updated in July 2021, that sub-Saharan Africa bears approximately 40% of the global burden of STIs. Additionally, as per the study published in April 2021, by BMC Public Health, STI prevalence was 7.7% and did not differ by HIV status. Prevalence differed by syndrome (3.5% vaginal discharge, 1.5% genital ulcer, 2.1% lower abdominal pain, 0.2% inguinal bubo). Thus, the rising burden of sexually transmitted diseases is expected to increase the demand for contraception to avoid getting diseases, thereby propelling market growth.
Moreover the products launches by the key players are expcted to boost thw growth of the market. For instrance, in March 2022, Medicines360, Population Services International, and Society for Family Health launched Avibela (levonorgestrel-releasing intrauterine system) 52 mg hormonal intrauterine device in Nigeria.
However, the high cost of devices and treatment and side effects associated with the use of contraceptive drugs and devices are some of the factors that are likely to impede market growth over the forecast period.
Key Market Trends
The Oral Contraceptives Segment is Expected to Show Better Growth in the Forecast Years
Oral contraceptive pills are considered the easiest method of contraception in the industry. They prohibit implantation within the uterus if taken within 2-3 days of unsafe sexual contact. These are easily marketed across large regions by several companies and thus easily consumed by a large population.
According to WHO data updated in June 2021, around 214 million women of reproductive age in developing countries who want to avoid pregnancy are not using a modern contraceptive method. In Africa, 24.2% of women of reproductive age have an unmet need for modern contraception, as per the WHO estimates. Hence, the rising demand for contraceptives to avoid unintended pregnancies and rising government initiatives are expected to drive the market in the forecast period.
Moreover, as per the study published in January 2022 by Contraception and Reproductive Medicine, the awareness of emergency contraceptives among women of reproductive age in South America has increased. South Africa reported the level of emergency contraceptive (EC) awareness to be 57% compared to the previous year. Therefore, the rising awareness among the population about contraceptives is expected to increase the demand for contraceptive pills, which is expected to boost the market's growth over the forecast period.
South Africa is Expected to Show High Growth in the Forecast Years
South Africa has one of the highest numbers of HIV-infected adults and children in the world. The epidemic is generalized across the country's population and is primarily driven by sexual transmission.
As per the data updated in June 2021 by population.un.org, in 2021, nearly 51% of women aged 15-49 years in Southern Africa used contraceptives - either traditional or modern methods. The region registered the highest contraceptive prevalence rate in Africa. Thus, the increasing usage of contraceptives is expected to increase in South Africa which is further expected to boost the growth of the market over the forecast period in the country.
Moreover, as per the data updated in June 2022, by Statistics South Africa, as of 2021, approximately three percent of females aged 14 to 19 years in South Africa stated that they were going through different stages of pregnancy within the last 12 months. The prevalence of pregnancy increased with age. Moreover, as per the study published in December 2021 by the National Library of Medicine, the prevalence of unintended pregnancy was significantly higher among adolescent girls aged 15 19 years (76.3%) and young women aged 20 24 years (56.5%). Thus, the rising burden of unintended pregnancies among young age women and girls is expected to boost the demand for contraceptive drugs and devices which in turn is anticipated to boost the market growth over the forecast period in South Africa.
Thus, the above-mentioned factors, such as the increasing usage of contraceptives coupled with the rising number of unintended pregnancies, are expected to boost the growth of the market studied in the country.
Competitive Landscape
Africa's Contraceptive Drug and Devices Market is moderately competitive, and several local and international companies deal with contraceptives. The major players in the Africa contraceptive drugs and devices market are Allergan PLC, Bayer AG, Johnson & Johnson, Lupin Limited, Merck & Co. Inc., Mylan NV, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.
Major Players
-
Bayer AG
-
Merck & Co. Inc.
-
Pfizer Inc.
-
Teva Pharmaceutical Industries Ltd.
-
AbbVie
*Disclaimer: Major Players sorted in no particular order
Recent Developments
- In October 2022, The Total Family Health Organisation (TFHO) launched the 'Ebony Condom' in Accra, calling Ghanaians to patronize quality brands to enhance their ability to prevent Sexually Transmitted Diseases (STD's) as well as unwanted pregnancies.
- In February 2022, Mithra and Searchlight Pharma launched Myring, Mithra's vaginal contraceptive ring.
Africa Contraceptives Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Incidence of the STDs and Unplanned Pregnancies
- 4.2.2 Rise in Government Initiatives
-
4.3 Market Restraints
- 4.3.1 Side Effects Associated with the Use of Contraceptive Drugs and Devices
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value in USD million)
-
5.1 By Products
- 5.1.1 By Drugs
- 5.1.1.1 Oral Contraceptives
- 5.1.1.2 Topical Contraceptives
- 5.1.1.3 Contraceptive Injectable
- 5.1.2 By Device
- 5.1.2.1 Condoms
- 5.1.2.2 Diaphragms
- 5.1.2.3 Cervical Caps
- 5.1.2.4 Sponges
- 5.1.2.5 Vaginal Rings
- 5.1.2.6 IUD
- 5.1.2.7 Other Devices
-
5.2 By Gender
- 5.2.1 Male
- 5.2.2 Female
-
5.3 Geography
- 5.3.1 South Africa
- 5.3.2 Nigeria
- 5.3.3 Morocco
- 5.3.4 Uganda
- 5.3.5 Democratic Republic of the Congo
- 5.3.6 Rest of South Africa
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 AbbVie
- 6.1.2 Bayer AG
- 6.1.3 Johnson & Johnson
- 6.1.4 Lupin Limited
- 6.1.5 Merck & Co. Inc.
- 6.1.6 Mylan N.V.
- 6.1.7 Pfizer Inc.
- 6.1.8 Teva Pharmaceutical Industries Ltd
- 6.1.9 Medicines360
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityScope of the Report
As per the report's scope, contraceptive drugs and devices are used for birth control. Contraception is more commonly known as fertility and birth control, described as the method to avoid pregnancy. Africa Contraceptive Drug and Devices Market is segmented by Products (Drugs and Devices) and Gender (Male and Female), and Geography (South Africa, Nigeria, Morocco, Uganda, Democratic Republic of the Congo, Rest of South Africa). The report offers the value (in USD million) for the above segments.
| By Products | By Drugs | Oral Contraceptives |
| Topical Contraceptives | ||
| Contraceptive Injectable | ||
| By Products | By Device | Condoms |
| Diaphragms | ||
| Cervical Caps | ||
| Sponges | ||
| Vaginal Rings | ||
| IUD | ||
| Other Devices | ||
| By Gender | Male | |
| Female | ||
| Geography | South Africa | |
| Nigeria | ||
| Morocco | ||
| Uganda | ||
| Democratic Republic of the Congo | ||
| Rest of South Africa |
Africa Contraceptives Market Research FAQs
What is the current Africa Contraceptive Drugs and Devices Market size?
The Africa Contraceptive Drugs and Devices Market is projected to register a CAGR of 7.20% during the forecast period (2024-2029)
Who are the key players in Africa Contraceptive Drugs and Devices Market?
Bayer AG, Merck & Co. Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd. and AbbVie are the major companies operating in the Africa Contraceptive Drugs and Devices Market.
What years does this Africa Contraceptive Drugs and Devices Market cover?
The report covers the Africa Contraceptive Drugs and Devices Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Africa Contraceptive Drugs and Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Africa Contraceptive Drugs and Devices Industry Report
Statistics for the 2024 Africa Contraceptive Drugs and Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Africa Contraceptive Drugs and Devices analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
